… a randomized, controlled trial in which nirmatrelvir was evaluated in … However, data regarding
the effectiveness of nirmatrelvir … effectiveness of nirmatrelvir in preventing severe Covid-19 …

… Using a retrospective cohort study design, we aimed to evaluate the effectiveness of
molnupiravir and nirmatrelvir/ritonavir in patients with SARS-CoV-2 who were highly vulnerable. …

… We identified patients with COVID-19 who received either molnupiravir (800 mg … nirmatrelvir
plus ritonavir (nirmatrelvir 300 mg and ritonavir 100 mg twice daily for 5 days, or nirmatrelvir …

… or older with mild-to-moderate COVID-19 who are at risk of progression to … effectiveness
of nirmatrelvir–ritonavir in preventing hospital admissions and death in people with COVID-19 …

… who are at high risk of disease progression, the current analysis focuses on their effectiveness
in hospitalised patients with COVID-19 who do not initially require any oxygen therapy on …

… nirmatrelvir–ritonavir (Paxlovid™), for the treatment of patients with mild‐to‐moderate COVID‐19
… and evaluate the efficacy and safety of nirmatrelvir–ritonavir in COVID‐19 patients, and …

… in preventing progression to severe COVID-19. Our objective was to evaluate the
effectiveness of nirmatrelvir–ritonavir in preventing severe COVID-19 while Omicron and its …

… patients who are at high risk of disease progression, the current analysis focuses on their
effectiveness in hospitalized patients with COVID-19 who do not initially require any oxygen …

… of the effectiveness of the … effectiveness of sotrovimab, molnupiravir, and nirmatrelvir-ritonavir
in preventing hospital admission and death in higher-risk patients (Fig. 1) with COVID-19 in …

… or unvaccinated high-risk individuals with COVID-19. Data from ongoing and future …
effectiveness and safety of nirmatrelvir-ritonavir and help improve treatment guidelines for COVID-19. …